Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats

Neuroscience Letters

Volumn 583, Issue , 2014, Pages 16-20

  Castaneda Arellano R ^a   Feria Velasco, A I ^a   Rivera Cervantes, M C ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

EpoR phosphorylation; Erythropoietin; Intranasal delivery; Ischemia; Neuroprotection

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN; TYROSINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HIPPOCAMPUS; LOW DRUG DOSE; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN ISCHEMIA; CELL SURVIVAL; CYTOPROTECTION; ERYTHROPOIETIN; HIPPOCAMPUS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RATS, WISTAR; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; TYROSINE;

EID: 84907517619     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.09.013     Document Type: Article

References (33)

1. Metha S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev. 2007, 54:34-66.
2. Sanchez P.E., Fares R.P., Risso J.J., Bonnet C., Bouvard S., Le-Cavorsin M., Georges B., Moulin C., Belmeguenai A., Bodennec J., Morales A., Pequignot J.M., Baulieu E.E., Levine R.A., Bezin L. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. PNAS 2009, 106:9848-9853.
3. Zhang F., Signore A.P., Zhou Z., Wang S., Cao G., Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J. Neurosci. Res. 2006, 83:1241-1251.
4. Dame C., Juul C.E., Christensen R.D. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol. Neonate. 2001, 79:228-235.
5. Genc S., Koroglu T.F., Genc K. Erythropoietin as a novel neuroprotectant. Restor. Neurol. Neurosci. 2004, 22:105-119.
6. Miura O., Cleveland J.L., Ihle J.N. Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol. Cell. Biol. 1993, 13:1788-1795.
7. Mulcahy L. The erythropoietin receptor. Semin. Oncol. 2001, 28:19-23.
8. Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95.
9. Brines M., Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J. Intern. Med. 2008, 264:405-432.
10. Wang Y., Zhang Z.G., Rhodes K., Renzi M., Zhang R.L., Kapke A., Lu M., Pool C., Heavner G., Chopp M. Br. J. Pharmacol. 2007, 151:1377-1384.
11. Zhang F., Xing J., Liou A.K., Wang S., Gan Y., Luo Y., Ji X., Stetler R.A., Chen J., Cao G. Enhanced delivery of erythropoietin across the blood-brain barrier for neuroprotection against ischemic neuronal injury. Transl. Stroke Res. 2010, 1:113-121.
12. Alcalá-Barraza S.R., Lee M.S., Hanson L.R., McDonald A.A., Frey W.H., McLoon L.K. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J. Drug Target 2010, 18:179-190.
13. Teste I.S., Tamos Y.M., Cruz Y.R., Cernada A.M., Rodríguez J.C., Martínez N.S., Antich R.M., González-Quevedo A., Rodríguez J.C. Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil. Sci. World J. 2012, 2012(607498):12.
14. Yu Y.P., Xu Q.Q., Zhang Q., Zhang W.P., Zhang L.H., Wei E.Q. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci. Lett. 2005, 387:5-10.
15. Sosa I., García Rodríguez J.C., Santana J., Subiros N., González C., Rodríguez Y., Rodríguez J. Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacologyonline 2006, 1:100-112.
16. Fletcher L., Kohli S., Sprague S.M., Scranton R.A., Lipton S.A., Parra A., Jimenez D.F., Digicaylioglu M. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. J. Neurosurg. 2009, 111:164-170.
17. Smith M.L., Bendek G., Dahlgren N., Rosen I., Wieloch T., Siesjo B.K. Models for studying long-term recovery following forebrain ischemia in the rat. 2. A 2-vessel occlusion model. Acta Neurol. Scand. 1984, 69:385-401.
18. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami C., Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
19. Villa P., van Beek J., Larsen A.K., Gerwien J., Christensen S., Cerami A., Brines M., Leist M., Ghezzi P., Torup L. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by non-erythropoietic erythropoietin derivatives. J. Cereb. Blood Flow. Metab. 2007, 27:552-563.
20. Brines M.L., Ghezzi P., Keenan S. Erythropoietin cross the blood brain barrier to protect against experimental brain injury. PNAS 2000, 97:10526-10531.
21. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M.L., Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002, 952:128-134.
22. Moskowitz M.A., Lo E.H., Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010, 67:181-198.
23. Jones K., Senft J.A. An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide. J. Histochem. Cytochem. 1985, 33:77-79.
24. Meng Y., Xiong Y., Mahmood A., Zhang Y., Qu C., Chopp M. Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats. J. Neurosurg. 2011, 115:550-560.
25. Spandou E., Papoutsopoulou S., Soubasi V., Karkavelas G., Simeonidou C., Kremenopoulos G., Guiba-Tziampiri O. Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain. Brain Res. 2004, 1021:167-172.
26. Chen Z.Y., Asavaritikrai P., Prchal J.T., Noguchi C.T. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J. Biol. Chem. 2007, 282:25875-25883.
27. Sola A., Rogido M., Lee B.H., Genetta T., Wen T.C. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr. Res. 2005, 57:481-487.
28. Campana W.M., Myers R.R. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur. J. Neurosci. 2003, 18:1497-1506.
29. Hellewell S.C., Ya E.B., Alwis D.S., Bye N., Morganti-Kossmann M.C. Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor. J. Neuroinflamm. 2013, 18:10-156.
30. Kawakami M., Sekiguchi M., Sato K., Kozaki S., Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 2001, 276:39469-39475.
31. Digicaylioglu M., Garden G., Timberlake S., Fletcher L., Lipton S.A. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. PNAS 2004, 101:9855-9860.
32. Velly L., Pellegrini L., Guillet B., Bruder N., Pisano P. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword?. Pharmacol. Ther. 2010, 128:445-459.
33. Lipton S.A. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 2007, 8:803-808.